Oramed Pharmaceuticals Inc. Logo

Oramed Pharmaceuticals Inc.

Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.

ORMP | TA

Overview

Corporate Details

ISIN(s):
US68403P2039
LEI:
Country:
Israel
Address:
20 Mamilla Avenue, 9414904 Jerusalem
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company specializing in the development of oral drug delivery systems. Established in 2006, the company leverages its proprietary platform technology to transform injectable drugs into oral therapies, aiming to enhance patient comfort, compliance, and safety. Its flagship product is an oral insulin capsule for the treatment of type 2 diabetes, which has undergone extensive clinical development. Oramed's primary focus is on providing non-invasive alternatives to injected medications, particularly for chronic conditions like diabetes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-22 09:42
Post-Annual General Meeting Information
Other Report or Announcement
English 118.7 KB
2025-08-22 09:42
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-08-22 09:41
Registration Form
Other Report or Announcement
English 181.3 KB
2025-08-22 09:41
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-08-17 15:18
Foreign Filer Report
FORM 10-Q- FINANCIAL STATEMENTS AS OF JUNE 30, 2025
English 36.4 KB
2025-08-17 15:16
Major Shareholding Notification
Form 13G
English 93.7 KB
2025-08-17 15:16
Foreign Filer Report
Form 13G
English 36.4 KB
2025-07-23 17:53
Delisting Announcement
Option Agreement for the Repurchase of Warrants
English 316.7 KB
2025-07-23 17:53
Foreign Filer Report
Option Agreement for the Repurchase of Warrants
English 36.4 KB
2025-07-18 14:52
Proxy Solicitation & Information Statement
Other Report or Announcement
English 1.4 MB
2025-07-18 14:52
Proxy Solicitation & Information Statement
Other Report or Announcement
English 36.4 KB
2025-07-18 14:51
Registration Form
Other Report or Announcement
English 448.1 KB
2025-07-18 14:51
Registration Form
Other Report or Announcement
English 36.4 KB
2025-07-18 14:50
Annual / Quarterly Financial Statement
Other Report or Announcement
English 359.9 KB
2025-07-18 14:50
Foreign Filer Report
Other Report or Announcement
English 36.4 KB

Automate Your Workflow. Get a real-time feed of all Oramed Pharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oramed Pharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oramed Pharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Monopar Therapeutics Logo
Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.
United States of America
MNPR
Monte Rosa Therapeutics, Inc. Logo
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
United States of America
GLUE
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea
322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan
4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan
4885
MUSTANG BIO, INC. Logo
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
United States of America
MBIO
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea
017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America
NBTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.